Valuation
- Market cap
- 7,970,000
- Revenue TTM
- $0
- Net income TTM
- $-9,000,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 208,283
- Avg volume
- 108,038
- Day's range
- $1.01 – $1.14
- Shares out
- 7,246,000
- Stochastic %K
- 46%
- Beta
- 0.74
- Analysts
- Strong Sell
- Price target
- $5.00
Company profile
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating prima...
Show more
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 972 77 331 0156
- Website
- https://www.chemomab.com
- Address
- Building C, 10th Floor 10 Habarzel Street, Tel Aviv-Yafo, Israel
Latest news
No headlines yet.
